Table 2.

Sensitivity analysis for primary and key secondary end points

Sensitivity Analysis	Mean±SEM eGFR Change (ml/min per 1.73 m2) (95% Confidence Interval)			P Value
	Placebo (n=80)	Bardoxolone Methyl (n=77)	Difference between Treatment Groups
Year 2 primary end point (week 100 eGFR change)
Control-based multiple imputation	−8.5±1.5 (−11.4 to −5.6)	−1.4±1.6 (−4.5 to 1.7)	7.1±2.1 (2.9 to 11.3)	0.001
Tipping point analysis: bardoxolone week 100 shift=–22 ml/min per 1.73 m2	−8.5±1.7 (−11.7 to −5.3)	−3.8±1.7 (−7.2 to −0.4)	4.7±2.4 (0.0 to 9.4)	0.05
Year 2 key secondary end point (week 104 eGFR change)
Control-based multiple imputation	−10.8±1.3 (−13.4 to −8.2)	−7.8±1.4 (−10.6 to −5.0)	3.0±1.8 (−0.5 to 6.4)	0.09
Post hoc analysis using all available eGFR values collected approximately 104 weeks after randomization	−10.4±1.3 (−13.0 to −7.9)	−8.9±1.3 (−11.6 to −6.3)	1.5±1.7 (−1.9 to 4.9)	0.38
Post hoc imputation for patients progressing to kidney failure
Week 104 eGFR=5 ml/min per  1.73 m2	−11.5±1.3 (−14.2 to −8.9)	−7.1±1.5 (−10.1 to −4.1)	4.4±1.9 (0.7 to 8.2)	0.02
Week 104 eGFR=0 ml/min per  1.73 m2	−11.8±1.4 (−14.5 to −9.1)	−7.4±1.6 (−10.5 to −4.3)	4.4±2.0 (0.5 to 8.3)	0.03